Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After Recusal, Schnedar Leaving CDER Compliance Office

This article was originally published in The Pink Sheet Daily

Executive Summary

Cynthia Schnedar decides to leave several weeks after FDA determined that her husband's promotion could create conflicts of interest.

You may also be interested in...

US FDA’s New Compliance Chief Donald Ashley Brings International Law Enforcement Experience

Ashley's many years in the Department of Justice’s Office of International Affairs should be a plus for agency's globalization efforts.

Despite Globalization, Three Quarters of Serious Inspection Issues FDA Found Were in US

Interactive map, charts provide details on our analysis of FDA 2009-2014 inspection results data showing that even as the agency responded to the threat of poor drug quality abroad, it was more successful at finding serious quality issues during its much more numerous domestic inspections.

Show Me The Money: FDA Recruitment Efforts Challenged By Government Salaries

FDA’s Center for Drugs continues to operate under a staffing shortage at a time when it faces tremendous pressure to implement new authorities. In some cases, that’s left Janet Woodcock scrambling to find senior managers that can lead top CDER initiatives. Direct hiring authority has helped, but it doesn’t fully address FDA’s recruiting challenges. There’s still too much red tape – and not enough money.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts